Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Identification and Care of Patients with Hantavirus Disease

Date:Thursday, June 30, 2016


Barbara Knust, DVM, MPH, DCAVPM
Office of Infectious Diseases
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Gregory Mertz, MD
Professor Emeritus
Department of Internal Medicine
University of New Mexico

Michelle Harkins, MD
Associate Professor of Medicine
Division Chief, Pulmonary, Critical Care, and Sleep Medicine
Department of Internal Medicine
University of New Mexico


Hantavirus infection in the United States can cause severe and life-threatening illness, requiring rapid assessment, presumptive diagnosis, and high-level supportive care of respiratory and cardiac functions. Hantavirus infection causes a cardiopulmonary syndrome, which includes rapid accumulation of pulmonary edema following a flu-like prodrome. Approximately 37% of cases end in death. Although hantavirus disease is rare, clinicians should be aware of the risk factors, clinical picture, and essential care elements. During this COCA call, clinicians will learn about the epidemiology, diagnosis, and clinical care of patients with hantavirus disease in the United States.


At the conclusion of the session, the participant will be able to accomplish the following:

  • Describe the risk factors, endemic areas, and incubation period of hantavirus infection
  • Identify the clinical presentation and methods to identify a patient with hantavirus in the clinical setting
  • Understand the parameters of clinical management and critical care for patients with hantavirus

Call Materials

Additional Resources

Call Format

  • Audio conference call on 6/30/16: 2:00 – 3:00 PM EDT
  • Web-on-demand training after 3:00 PM EDT on 6/30/16
  • Materials: PowerPoint slide set

Accreditation Statements

Continuing Education

“WC2286” for attendees who participate in the live call (must be completed by July 30, 2016)
“WD2286” for attendees who participate in the online presentation (must be completed by July 30, 2018)

Target Audience

  • Physicians
  • Nurses
  • Pharmacists
  • Veterinarians
  • Physician Assistants
  • Health Educators
  • Other Clinicians


Additional Information

  • Contact
  • Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communications Branch
  • Method of Participation:You may participate in the educational activity by viewing the program information above.
  • Fees:COCA continuing education credits are free.

Accreditation Statements

CME:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE:The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity provides 1.0 contact hour.

IACET CEU:The Centers for Disease Control and Prevention is authorized by IACET to offer 1.0 CEU’s for this program.

CECH:Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

Image of acpe logo.CPE:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-16-154-L04-P and enduring 0387-0000-16-154-H04-P course category.

Course Category: This activity has been designated as knowledge-based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

AAVSB/RACE:This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education in the jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE Program at if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.

CDC is an approved provider of CPH Recertification Credits by the National Board of Public Health Examiners. Effective October 1, 2013, the National Board of Public Health Examiners (NBPHE) accepts continuing education units (CEU) for CPH recertification credits from CDC. Please select CEU as your choice for continuing education when registering for a course on TCEOnline. Learners seeking CPH should use the guidelines provided by the NBPHE for calculating recertification credits. For assistance please contact NBPHE at

There is no cost for this program.

DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC does not accept commercial support.